The critical role for ADP in arterial thrombogenesis was established by the clinical success of P2Y 12 antagonists, currently used at doses that block 40-50% of the P2Y 12 on platelets.
Introduction
Platelets are critical mediators of primary hemostasis through adhesion, aggregation, and subsequent thrombus formation induced by collagen, vWF, thrombin, and other factors exposed at sites of vascular injury. This function of platelets can become pathological in atherosclerotic arteries, causing vascular occlusions resulting in stroke or myocardial infarction. Two antiplatelet strategies have proven to be successful for the prevention of major arterial thrombosis. One strategy targets the glycoprotein IIb-IIIa (GP IIb-IIIa) complex (tirofiban, abciximab, eptifibatide), the platelet GP receptor mediating platelet aggregation. The clinical benefit of GP IIb-IIIa antagonists in acute settings is mediated by inhibition of both vWF-and fibrinogen-GP IIb-IIIa interactions, thereby preventing thrombus growth and stability, respectively (1) . The other strategy uses thienopyridine drugs (e.g., ticlopidine or clopidogrel) to target the recently identified ADP receptor (P2Y 12 ) (2). P2Y 12 is the G αi -coupled receptor mediating inhibition of adenylyl cyclase and is essential for stabilization of platelet aggregates. This receptor has been shown to be defective in a patient with a mild bleeding disorder and abnormal ADPinduced aggregation (2) . A second ADP receptor, P2Y 1 , has also been identified. This receptor couples to G αq and is responsible for mediating platelet shape change and ADP-induced aggregation by mobilization of intracellular calcium (3) .
Although it is readily apparent why GP IIb-IIIa antagonists inhibit thrombosis, it is less apparent why P2Y 12 antagonists provide a therapeutic benefit. First, ADP is considered a weak platelet agonist. Second, ticlopidine and clopidogrel are used at doses that block ADP-mediated ex vivo aggregation by only 40-50% (4), and although they showed clinical benefit alone (5), they are more efficacious when used in combination with aspirin (ASA) (6) . Other studies, however, have established that ADP is involved in multiple steps of platelet thrombosis. Firstly, ADP is released from dense granules upon platelet activation: the secreted ADP constitutes a positive-feedback loop in the setting of platelet aggregation independent of the agonist used (7, 8) and contributes to the recruitment of platelets to a growing thrombus as evidenced by the effect of soluble ecto-ADPase/CD39 in vitro (9) and in vivo (10) . Secondly, P2Y 12 and its cognate G i -coupled protein (Gi α2 ) are probably directly involved in the signaling events generated by other platelet receptors such as GP VI (11) and GP Ibα (12) .
The critical role for ADP in arterial thrombogenesis was established by the clinical success of P2Y 12 antagonists, currently used at doses that block 40-50% of the P2Y 12 on platelets. This study was designed to determine the role of P2Y 12 in platelet thrombosis and how its complete absence affects the thrombotic process. P2Y 12 -null mice were generated by a gene-targeting strategy. Using an in vivo mesenteric artery injury model and real-time continuous analysis of the thrombotic process, we observed that the time for appearance of first thrombus was delayed and that only small, unstable thrombi formed in P2Y 12 -/-mice without reaching occlusive size, in the absence of aspirin. Platelet adhesion to vWF was impaired in P2Y 12 -/-platelets. While adhesion to fibrinogen and collagen appeared normal, the platelets in thrombi from P2Y 12 -/-mice on collagen were less dense and less activated than their WT counterparts. P2Y 12 -/-platelet activation was also reduced in response to ADP or a PAR-4-activating peptide. Thus, P2Y 12 is involved in several key steps of thrombosis: platelet adhesion/activation, thrombus growth, and stability. The data suggest that more aggressive strategies of P2Y 12 antagonism will be antithrombotic without the requirement of aspirin cotherapy and may provide benefits even to the aspirin-nonresponder population.
This suggests a direct role for P2Y 12 not only in thrombus stabilization but also in the recruitment of circulating platelets onto a thrombogenic surface (vessel wall injury and adhering platelets).
This study was designed to determine the role of P2Y 12 in platelet thrombosis and to determine how the complete absence of this ADP receptor affects the thrombotic process. Using P2Y 12 -deficient mice, our in vivo and ex vivo studies show that P2Y 12 is involved in thrombus growth and stability and that these activities are mediated by mechanisms involving both platelet adhesion and activation. We also find that the total deficiency of P2Y 12 markedly impacts in vivo thrombosis, even in the absence of ASA.
Methods

Generation of P2Y 12
-/-mice. The P2Y 12 targeting vector was prepared from genomic clones containing the mouse P2Y 12 gene. A bacterial artificial chromosome (BAC) clone containing the murine P2Y 12 (mP2Y 12 ) sequence was amplified by PCR screening of a mouse 129/Sv library (Incyte Genomics Inc., St. Louis, Missouri, USA) using primers derived from the coding sequence of mP2Y 12 . A 15-kb HindIII fragment was identified from the mouse BAC clone, which contained the mP2Y 12 locus. Using PCR primers, a 5′ HindIII site and a 3′ Xba site were introduced to generate a 4-kb fragment just upstream of the ATG initiation codon for mP2Y 12 . Similarly, a XhoI site and NotI site were introduced by PCR to generate a 6-kb 3′ arm. Both of these fragments were subcloned into the pLNL vector such that they flanked a neomycin resistance gene (neo) (Figure 1a) . The vector was linearized with PvuI and introduced into the ES cell line E14Tg2a (derived from 129/Ola) by electroporation, and neomycinresistant clones were selected in media containing G418. DNA was isolated from surviving colonies, digested with XbaI, and assessed by Southern blot analysis using a probe corresponding to a DNA sequence located downstream of the targeting construct. Chimeric mice were generated with P2Y 12 -targeted ES cell lines and were bred to C57BL/6 mice. Mice with the targeted mutation were identified by Southern blot analysis or PCR and intercrossed with siblings that inherited the WT 129 P2Y 12 allele. Control and experimental mice were then obtained by intercross of the heterozygous mice derived from those sibling intercrosses.
Hemostatic parameters. Aggregation using plateletrich plasma (PRP) was measured turbidimetrically using a Chronolog aggregation analyzer (Chronolog Corp., Havertown, Pennsylvania, USA) following calibration with platelet-poor plasma, at a stirring speed of 800 rpm. Aliquots (250 µl) of PRP were placed in cuvettes containing magnetic stirrer bars, warmed at 37°C, and stirred for 1 minute to obtain a stable baseline. Aggregation was induced by either ADP (0.5 or 10 µM), collagen (1 or 20 µg/ml), or murine TRAP (mTRAP) (AYPGKF; 1 or 2.5 mM), and change in light transmittance was recorded for 6 minutes. Inhibition of cyclooxygenase by ASA was confirmed by obtaining mouse PRP 2 hours after ASA treatment and measuring aggregation induced by 500 µM arachidonic acid (Cayman Chemical Inc., Ann Arbor, Michigan, USA).
Mice used for bleeding time were sex-matched littermates of heterozygous breeding pairs of a mixed 129/Sv and C57BL/6J background. Genotyping was performed after the bleeding time study by an investigator blinded to the experiment. did not reoccur within 60 seconds of cessation, bleeding was considered stopped.
Determination of cAMP. Platelet cAMP levels were measured using the cAMP-Screen ELISA System (Perkin-Elmer Applied Biosystems, Foster City, California, USA). Following incubation with 500 µM 3-isobutyl-1-methylxanthine (Sigma-Aldrich, St. Louis, Missouri, USA) for 10 minutes at 37°C, mouse washed platelets (2.5 × 10 8 /ml, prepared as previously described) (13) were treated with 10 µM ADP (SigmaAldrich) or 0.001, 0.1, or 10 µM epinephrine (Burns Veterinary Supply, Farmers Branch, Texas, USA) in the presence of 50 µM forskolin (Sigma-Aldrich) for 10 minutes. Reactions were terminated, processed, and quantitated according to manufacturer's instructions.
Intravital microscopy. Blood sampling and platelet preparation were performed as described previously with minor modifications (14) . Blood (approximately 800 µl per mouse) was collected in polypropylene tubes containing 140 µl of acid-citrate-dextrose (38 mM citric acid, 75 mM trisodium citrate, and 100 mM dextrose), 400 µl of washing buffer (129 mM NaCl, 13.6 mM trisodium citrate, 11.1 mM dextrose, 1.6 mM KH 2 PO 4 , 0.02 U/ml apyrase, pH 6.8), and 1 µM PGE 1 (Sigma-Aldrich). PRP was obtained by centrifugation at 220 g for 7 minutes. The plasma and buffy coat were gently transferred to a fresh polypropylene tube containing 0.7 ml of the washing buffer and centrifuged at 160 g for 5 minutes. The same operation was repeated once in order to pellet contaminating leukocytes and red blood cells. The supernatant was transferred to two polypropylene tubes containing 4 ml of washing buffer. After centrifugation at 2,000 g for 12 minutes, the platelet pellet was resuspended in resuspension buffer (137 mM NaCl, 4 mM KCL, 0.5 mM MgCl 2 , 0.5 mM sodium phosphate, 11.1 mM dextrose, 0.1% BSA, 10 mM HEPES, pH 7.4). Platelets were fluorescently labeled with calcein AM (0.25 µg/ml; Molecular Probes Inc., Eugene, Oregon, USA) for 20 minutes at RT and infused (5 × 10 9 platelets/kg) through the tail vein.
In some experiments, ASA was administered in WT and P2Y 12 +/-mice 2 hours before FeCl 3 -induced injury. Epinephrine (blood volume of the recipient mouse [13-17 g] estimated at 1 ml), was injected 15 minutes before injury at 1, 10, and 50 µM in WT and P2Y 12 -/-mice. In another experiment, 30 minutes before 50 µM epinephrine infusion, WT and P2Y 12 -/-mice were administered the GP IIb-IIIa inhibitor CT51464 (15) by oral gavage (50 mg/kg). Immediately after infusion of fluorescent platelets into mice of matching genotype, mice were anesthetized and mesenteric arteries (85-150 µm diameter) were studied. Vessels with a shear rate of 1,000-1,400 per second were selected using an Optical Doppler Velocimeter (Texas A&M University, System Health Science Center, Cardiovascular Research Institute, College Station, Texas, USA). Arteries were visualized using a Carl Zeiss (Oberkochen, Germany) Axiovert S100 inverted microscope (objective ×20) equipped with a 250 -W HBO fluorescent lamp source (Opti Quip, Highland Mills, New York, USA) with a narrow-band FITC filter set (Chroma Technology Corp., Brattleboro, Vermont, USA) and a Hamamatsu (Tokyo, Japan) chilled CCD C5985 intensified camera connected to a VHS video recorder (Sony SVO-9500MD). One artery per mouse was filmed for 2 minutes before vessel wall injury. Vessel wall injury was generated using a modified FeCl 3 -induced thrombosis protocol. A 2 × 1-mm filter paper was immersed into a 12.5% FeCl 3 solution for 2 minutes and then placed over the artery for 7 minutes. After 7 minutes, the paper was removed and the vessel covered with NaCl at 37°C. Platelet vessel wall interactions were then recorded for 33 minutes or until full occlusion occurred and lasted for more than 20 seconds.
Video analysis. Platelet vessel wall interactions and thrombus formation were analyzed in real time using Simple PCI software (Compix Inc., Imaging System, Cranberry Township, Pennsylvania, USA). In summary, the mean fluorescent intensity (which reflects the kinetics of the thrombotic process) at the site of vessel wall injury was recorded on 2 frames per second for 40 minutes and plotted automatically versus time. Each experiment was simultaneously recorded on videotape and analyzed by the computer. Hence, this software allows continuous monitoring of the thrombotic process for each animal.
Perfusion chamber experiments. The murine ex vivo perfusion chamber protocol has been described previously (16) . Briefly, non-anticoagulated blood was collected from the vena cava of anesthetized mice and perfused for 2.5 minutes through either fibrinogencoated (500 µg/ml in saline solution incubated for 2 hours at RT; Sigma-Aldrich) or human type III collagen-coated (Sigma-Aldrich) capillary chambers. Capillary chambers with a diameter of 345 µm were used to establish a shear rate of 871/s (flow rate of 212 µl/min) (17) . To study binding of murine GP Ibα to human vWF (18, 19) , washed platelets (3 × 10 8 /ml supplemented with 1 mM CaCl 2 ) from WT or P2Y 12 -deficient mice were incubated with 6 µg/ml botrocetin (19) , with or without 10 µM epinephrine, and perfused through human vWF-coated (100 µg/ml incubated at 4°C overnight; kind gift of Zaverio Ruggeri, The Scripps Research Institute, La Jolla, California, USA) capillary chambers at 871/s for 4 minutes. For perfusion over fibrinogen and vWF, the number of platelets present in a 300 × 150-µm window was determined using Simple PCI software. For perfusion over collagen, P2Y 12 -/-mice were infused intravenously with 10 mg/kg ASA (Aspegic; Sanofi-Synthelabo Inc., Malvern, Pennsylvania, USA) 2 hours before blood perfusion. Epinephrine (50 µM) was injected in ASA-treated P2Y 12 -/-mice 10 minutes before ex vivo blood perfusion. Mean thrombus volume (micrometer cubed per micrometer squared, corresponding to the mean area of all thrombi divided by their mean All procedures conformed to institutional guidelines and to the Guide for the Care and Use of Laboratory Animals (The NIH, Bethesda, Maryland, USA).
Statistical analysis. Bleeding time values are expressed as mean plus or minus SEM. The effect of various concentrations of epinephrine in vivo as well as the bleeding time study were tested by one-way ANOVA and comparison analyzed using Dunnett multiple comparison tests. Statistical significance of the difference between two groups of data was tested by student t tests.
Results
Generation of the P2Y 12
-/-mice and hemostatic parameters. We generated P2Y 12 -null mice by a gene-targeting strategy (Figure 1, a and b) . Mice lacking P2Y 12 were viable, fertile, and produced viable offspring and normal litter sizes. Platelet counts in P2Y 12 -/-mice, as well as counts for other blood cell lineages, were essentially identical to WT mice (data not shown). We compared the aggregation responses of PRPs from WT, P2Y 12 +/-, and P2Y 12 -/-mice using 0.5 µM and 10 µM ADP (Figure 2, a and b) . As expected, lack of P2Y 12 dramatically affected the aggregation process induced by ADP in the P2Y 12 -/-mice at both ADP concentrations, with results in the P2Y 12 +/-mice more similar to WT platelets. Shape change in response to either agonist was normal in both WT and P2Y 12 -deficient platelets, in agreement with a previous report (20) . We also examined aggregation in all three genotypes using 1 and 20 µg/ml collagen ( length of adhesion) was quantified on semithin cross sections and by mean gray level measurements at 5 mm from the proximal part of the capillary using Simple PCI software. were coated with human type III collagen and perfused with non-anticoagulated blood (collected from the vena cava) for 2.5 minutes at 220 µl/min (840/s). Immediately after, capillaries were rinsed for 15 seconds, fixed in 2% paraformaldehyde at 4°C for 1 hour, rinsed three times with PBS/0.5% BSA, then incubated for 45 minutes either with FITC-conjugated antimouse P-selectin (1:25 dilution; PharMingen, San Diego, California, USA) or goat anti-human Gas6 (100 µg/ml; Santa Cruz Biotechnology Inc., Santa Cruz, California, USA), followed by TRITC-conjugated rabbit anti-goat Ab (1:1,000 dilution; Jackson ImmunoResearch Laboratories Inc., West Grove, Pennsylvania, USA). In some experiments, thrombi were fixed for 30 minutes, incubated for 1 hour with 1 mg/ml Alexa 488-fibrinogen (Molecular Probes Inc.), and rinsed four times with PBS/0.5% BSA.
FACS study of the level of GP IIb-IIIa activation. Washed platelets (± 1 mM CaCl 2 ) from WT and P2Y 12 -/-mice were incubated for 1 hour at 37°C with either saline, 0.6 mM murine TRAP (SynPep Corp., Dublin, California, USA), or 5 µM ADP, in the presence or absence of 1, 10, or 50 µM epinephrine and 200 µg/ml Alexa 488-fibrinogen (Molecular Probes Inc.). Analysis of platelet-bound Alexa 488-fibrinogen was performed using a FACSort flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, California, USA). +/-mice are consistent with those observed in patients that are heterozygous at the P2Y 12 locus (21, 22) who also display normal bleeding times.
As P2Y 12 couples to inhibition of adenylyl cyclase through G αi , we also examined the ability of ADP to repress forskolin-stimulated cAMP levels in washed platelets from WT, P2Y 12 +/-, and P2Y 12 -/-mice. As expected, no repression by ADP of forskolin-induced cAMP levels was observed in P2Y 12 -deficient mice ( Figure 3) ; however, the level of repression by ADP in P2Y 12 +/-platelets was similar to that of WT platelets, suggesting that approximately 50% of the level of P2Y 12 receptor is sufficient to mediate inhibition of adenylyl cyclase through the G αi pathway. Since epinephrine, which inhibits adenylyl cyclase through G αz in mouse platelets, can compensate for blockade or lack of P2Y 12 , we examined the ability of epinephrine (0.001-10 µM) to repress forskolin-stimulated cAMP levels in platelets from all three genotypes of mice. As seen in Figure 3 , no impairment of cAMP repression was observed in all three genotypes over a range of epinephrine concentrations.
In vivo thrombotic profile of P2Y 12 -/-mice. Using realtime continuous analysis of the thrombotic process, we observed that the time for appearance of first thrombus bigger than 20 µm was significantly delayed in P2Y 12 -/-(P = 0.0063 versus WT) and in P2Y 12 +/-(P = 0.0381 versus WT) (Figures 4a and 5a ), whereas the transient platelet interactions that immediately follow vessel wall injury (i.e., tethering and rolling) were not affected (data not shown). We found that P2Y 12 -/-mice developed a cyclic thrombotic process (Figure 4a ) with more than 50 thrombi of intermediate size (between 25 and 50 µm diameter) embolizing between the 8-15 minute period in contrast to the WT and heterozygous mice where only a few (three to five) large (>50 µm) thrombi embolized before occlusion (Figure 5b ). Time for occlusion was significantly increased in P2Y 12 -/-mice (P < 0.0001) because only one out of nine animals reached occlusion after 38 minutes (Figure 5c ). Interestingly, in heterozygous animals both time for appearance of first thrombus and time for occlusion were delayed compared with WT mice (Figure 5, a and c) . ASA infusion (10 mg/kg) had limited efficacy in both WT and P2Y 12 +/-mice ( Figure 5, b and c) . This dose of ASA was demonstrated to completely block arachidonic acid-induced aggregation in mouse platelets (data not shown). Epinephrine corrected the delay in time for appearance of P2Y 12 -/-mice at all three concentrations used (1, 10, and 50 µM; P < 0.001) and accelerated (at 10 and 50 µM) the thrombotic process in P2Y 12 -/-mice, but did not fully restore stability ( Figure  4b and Figure 5 , b and c). Although use of a GP IIb-IIIa inhibitor (CT51464) prevented occlusion in both WT and P2Y 12 -/-epinephrine-treated mice, some cyclic thrombotic process still occurred in the WT/epinephrine-treated group, but not in the P2Y 12 -/-mice ( Figure  4b and Figure 5b) .
In vitro and ex vivo profiles of P2Y 12 -/-platelet deposition. Because our in vivo results indicated that the appearance of thrombi was delayed in P2Y 12
-/-versus WT mice, we compared the adhesion/activation thrombus formation processes on purified proteins under high shear rate conditions in order to understand the role of P2Y 12 in these processes. vWF has a proven role in arterial thrombosis (23) : indeed, P2Y 12 -/-platelets adhered substantially less on vWF-coated surface, even in the absence of ASA, compared with WT cross sections and plotted against their respective gray level measurement (Figure 6c ). We confirmed that the antithrombotic activity of ASA synergized with that of P2Y 12 -/-mice because ASA-treated P2Y 12 -/-mice presented a profound reduction in thrombus volume (P < 0.001 versus WT), which was corrected upon 50 µM epinephrine infusion ( Figure  6d ). Because the shear rate was fixed by both the peristaltic pump and the diameter of the perfusion chamber, this excluded a possible involvement of a rheological effect of epinephrine. Although there were no significant differences in thrombus volume between P2Y 12 -/-and WT thrombi, P2Y 12 -/-thrombi formed over collagen were loosely packed and platelets present at the apex of the thrombi were less activated than in WT thrombi, as indicated by the platelets (Figure 6a ). This defect was fully corrected by 10 µM epinephrine, suggesting that activation of the G i pathway was the missing signaling event. Platelet adhesion over fibrinogen was not affected by the lack of P2Y 12 ( Figure 6b ). Ex vivo, platelet adhesion over collagen was slightly increased in the P2Y 12 -/-mice (40% ± 4.5% for P2Y 12 -/-versus 31.1% ± 1.5% for WT). Mean thrombus volume using whole blood from WT, P2Y 12 -/-, and ASA-treated WT or P2Y 12 -/-mice was obtained from -/-thrombotic process was characterized by constant embolization of thrombi greater than 25 µm and less than 50 µm (dotted bars) between 8 and 15 minutes after injury, whereas only a few large thrombi (greater than 50 µm, black bars) embolized in both WT and P2Y 12 +/-mice before occlusion of the blood vessel. Intravenous injection of epinephrine accelerated the thrombotic process but did not fully restore stability. When more than 50 thrombi embolized during the 7-minute period, a value of 50 was fixed. This explains the lack of error bars for the P2Y 12 -/-groups treated with 1 and 10 µM epinephrine. (c) Time for occlusion of mesenteric arteries. P2Y 12 deficiency significantly increased (P < 0.0001) the time for occlusion. P2Y 12 +/-mice presented an increased time for occlusion (P < 0.01 versus WT). ASA treatment of WT mice prolonged the time for occlusion (P < 0.05). Epinephrine (50 µM) restored occlusion in P2Y 12 -/-mice. GP IIb-IIIa antagonism in epinephrine-treated mice prevented occlusion, but was accompanied by severe bleeding at the site of vascular surgery (n = 5-12 animals). -/-mice was perfused over collagen at 871/s. Epinephrine infusion (50 µM) corrects the inhibition observed with the combination P2Y 12 deficiency/ASA uptake (10 mg/kg). Values were expressed as the mean ± SEM of at least six animals per group.*P < 0.001. staining for P-selectin, Gas6, and the decreased binding of Alexa 488-fibrinogen ( Figure 7 ).
FACS study of the level of platelet activation induced by various agonists. P2Y 12
-/-platelets activated either with murine TRAP or ADP were found to bind less fibrinogen compared with WT mice (Figure 8 ). Epinephrine (10 µM) induced GP IIb-IIIa activation as reported previously (24, 25) in both WT and P2Y 12 -/-platelets and potentiated fibrinogen binding in WT platelets activated by ADP. Treatment with epinephrine in ADP and mTRAP-activated P2Y 12 -/-platelets gave a pattern similar to that of WT platelets treated with either agonist alone. Epinephrine effects were observed at concentrations as low as 1 µM (data not shown).
Discussion
Although the combination therapy of thienopyridines/ASA represents a successful clinical strategy for the prevention of arterial thrombosis (26, 27) , the actual mechanistic basis for understanding how inhibitors of P2Y 12 act in vivo has been lacking. The role previously attributed to the platelet P2Y 12 receptor has been that of sustaining aggregation and stabilization of large aggregates, based on aggregometry studies with P2Y 12 antagonists and patients with defects in this receptor. A recent study has described the in vitro platelet phenotype of SP1999-deficient mice (P2Y 12 -/-mice) but lacked evaluation of the effect of P2Y 12 deficiency on the thrombotic process (20) . By using mice deficient in P2Y 12 , we now demonstrate that P2Y 12 is involved, to varying degrees, in each step of arterial thrombogenesis. The overall effect of loss of P2Y 12 -/-in mice translates into a delayed cyclic thrombotic process in which injured arteries are unable to occlude, even in the absence of ASA. It thus appears that the P2Y 12 -/-phenotype shares the phenotypes of both vWF -/-(absence of occlusion) and fibrinogen -/-(unstable thrombi) mice (1) .
P2Y 12 deficiency affects each step of the thrombotic process (Figure 9 ). First, platelet adhesion on vWF under high shear rates was decreased in P2Y 12 -/-mice, which likely represents a defect in the inside-out activation of GP IIb-IIIa. Our results in mice support those previously reported by Goto et al. (12) , who demonstrated that released ADP acting on P2Y 12 is important in activation of the process that leads to firm platelet adhesion on vWF. Since vWF has a proven role in platelet adhesion and platelet-platelet interactions, this likely accounts, in part, for the observed delayed thrombus formation in vivo. Second, there is an overall platelet activation defect observed on the surface of a growing thrombus in P2Y 12 -/-mice, as reflected by decreased expression of P-selectin and Gas6 and decreased fibrinogen binding on collagen-coated surfaces. As platelets release thrombogenic mediators such as CD40L and Gas6 upon activation (28, 29) , this could further reduce the thrombogenicity of a P2Y 12 -/-growing thrombus. In addition, a defect in platelet activation/secretion
Figure 7
Level of platelet activation at the apex of arterial thrombi. Thrombi formed after a 2.5-minute perfusion period of WT (a, c, and e) and P2Y 12 -/-(b, d, and f) blood at 840/s over collagen. Fixed (but not permeabilized) thrombi were stained for P-selectin (a and b), Gas6 (c and d), and with Alexa 488-fibrinogen (e and f).
Figure 8
Flow-cytometric analysis of Alexa 488-fibrinogen binding to resting platelets, 0.6 mM mTRAP-treated platelets, and 5 µM ADP-treated platelets in the presence or absence of 10 µM epinephrine-activated (Epi) and ADP plus epinephrine-activated platelets. Thick line represents P2Y 12 -/-platelets; thin line WT platelets. Epinephrine (1 and 10 µM) did not induce binding of Alexa 488-fibrinogen in absence of 1 mM CaCl 2 (not shown). The presence of epinephrine in ADP-and mTRAP-activated P2Y 12 -/-platelets gave a pattern similar to that of WT platelets treated with the same agonist in the absence of epinephrine. Data shown are representative of at least three experiments performed in duplicate.
may also result in a decreased amount of secreted vWF, a known important player of the thrombotic process (30) (31) (32) . Third, activation by mTRAP and ADP was impaired in P2Y 12 -/-mice. The combined consequences of these defects would be sufficient to cause a cyclic thrombotic process preventing arterial occlusion in vivo.
Because P2Y 12 and the adrenergic receptor both repress intracellular cAMP through G αi2 and G z and are both capable of activating Rap-1, which likely plays a role in GP IIb-IIIa activation (33, 34) , we investigated the physiological response of P2Y 12 -/-mice challenged with epinephrine. Stimulation of the platelet adrenergic receptor α 2a by epinephrine corrected the overall phenotype attributed to P2Y 12 deficiency except for thrombus stability in vivo. This observation suggests that although both G i and G z repress cAMP, there are unique features of the P2Y 12 /G i pathway that are critical for thrombus stability and that are not compensated by epinephrine/G z . Because epinephrine also contributes to GP IIb-IIIa activation, however, one cannot exclude that part of the correction is due to the circulation of preactivated platelets. Our FACS study confirmed that ADP and epinephrine signal via two different pathways (7, 35, 36) and that epinephrine potentiates the effect of ADP alone, even in WT mice. Interestingly, the defect in fibrinogen binding to P2Y 12 -/-platelets was more pronounced than that of G αi2 -/-platelets (13).
Another major finding is that even though P2Y 12 +/-mice display a significant increased time for in vivo occlusion, they have a normal bleeding time. ASA infusion in P2Y 12 +/-mice failed to confer a knockout phenotype. This likely indicates that some subtle differences exist between murine and human P2Y 12 activities because antithrombotic activity of ASA only partially modulated the P2Y 12 +/-phenotype in vivo, whereas it is known that ASA synergizes P2Y 12 antagonism in humans. Overall, our in vitro, ex vivo, and in vivo results using P2Y 12 -/-mice agree well with studies in humans using P2Y 12 antagonists, because mouse platelets behave similarly to human platelets in response to ADP (20) , except for lack of dense-granule release in mouse platelets compared with humans (37) .
The current thienopyridine P2Y 12 antagonists (clopidogrel and ticlopidine) require hepatic metabolism in order to block P2Y 12 , and recent studies have demonstrated that even a bolus dose in combination with ASA requires at least 6 hours to reach maximal antithrombotic activity (38, 39) . Furthermore, Gurbel et al. demonstrated that the normal dosing regimen of clopidogrel results in less than 40% blockade of ADP-induced aggregation and is highly variable between individuals (4). It is therefore conceivable that direct-acting P2Y 12 inhibitors with improved pharmacokinetic properties may achieve better efficacy if they target greater than 50% inhibition, as our in vivo results suggest.
The present study also highlights two main issues in regard to predicted therapeutic efficacy of P2Y 12 antagonists. First, we have found that total P2Y 12 deficiency dramatically affects the in vivo thrombotic process and ex vivo thrombosis on surfaces expressing vWF and collagen, both known components of atherosclerotic plaques. The data predict, therefore, that more efficient inhibition of P2Y 12 than is afforded by the currently available antagonists would be more efficacious, even though it is recognized that P2Y 12 antagonism does not inhibit thrombosis over tissue factor, a third highly thrombogenic constituent of an atherosclerotic plaque (40) . Second, higher concentrations of P2Y 12 antagonists or combined strategies of P2Y 12 antagonism coupled either to GP IIb-IIIa inhibitors (as observed on Figure 5c ) or direct thrombin inhibitors could represent an alternative strategy for the subpopulation of patients (10-30%) who don't respond to ASA (41) . 
